CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Last trade$61.05
Day change-$0.83 (-1.34%)
Day range$60.40 – $63.59
Volume797,517
Market cap$11.77B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$11.77B
Price / earnings
20.63×
Price / book
1.41×
Price / sales
2.78×
EV / sales
3.34×
EV / EBITDA
15.25×
Profitability
Earnings per share
$3.00
Return on assets
4.5%
Return on equity
6.85%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.31×
Current ratio
1.22×
Quick ratio
0.73×
Cash ratio
0.08×
Cash flow
Price / cash flow
11.39×
Price / free cash flow
17.36×
Free cash flow
$678M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for COO, quarterly periods
Line item
Q3 FY2026 Jul 31, 2026
Q2 FY2026 Apr 30, 2026
Q1 FY2026 Jan 31, 2026
Q4 FY2025 Oct 31, 2025
Q3 FY2025 Jul 31, 2025
Q2 FY2025 Apr 30, 2025
Q1 FY2025 Jan 31, 2025
Q4 FY2024 Oct 31, 2024
Revenue
$1.07B
$1.08B
$1.02B
$1.07B
$1.06B
$1B
$964.7M
$1.02B
Cost of revenue
$354.3M
$346.1M
$328.9M
$414.3M
$368.3M
$323.2M
$304.5M
$340.7M
Gross profit
$711.9M
$735.4M
$695.2M
$650.8M
$692M
$679.1M
$660.2M
$677.7M
Selling, general and administrative
$401.3M
$676.2M
$390.2M
$419.2M
$421.7M
$399M
$387.9M
$391.4M
Research and development
$41.6M
$42.5M
$44.3M
$41.4M
$44.6M
$45.5M
$40.7M
$37.7M
Total operating expenses
$489.9M
$766.4M
$482.4M
$510.4M
$516.3M
$494.3M
$478.2M
$479.3M
Operating income
$222M
-$31M
$212.8M
$140.4M
$175.7M
$184.8M
$182M
$198.4M
Interest expense
-$21.5M
-$20.9M
-$22.4M
-$24.4M
-$25.4M
-$24.2M
-$26M
-$27M
Income before taxes
$201.8M
-$48.4M
$192.2M
$116.8M
$151.9M
$144.5M
$153.3M
$168.6M
Income taxes
-$231M
$29.5M
$61.4M
$32.2M
$53.6M
$56.8M
$49M
$51.1M
Net income
$432.8M
-$77.9M
$130.8M
$84.6M
$98.3M
$87.7M
$104.3M
$117.5M
Net income attributable to common shareholders
$432.8M
-$77.9M
$130.8M
$84.6M
$98.3M
$87.7M
$104.3M
$117.5M
EBITDA
$316.7M
$64.4M
$308.3M
$238.8M
$271.1M
$277.4M
$273M
$289.4M
Basic earnings per share
$2.24
-$0.40
$0.67
$0.43
$0.49
$0.44
$0.52
$0.59
Diluted earnings per share
$2.24
-$0.40
$0.66
$0.43
$0.49
$0.44
$0.52
$0.59
Recent news
Company coverage with links to the original publishers.
Marker Therapeutics reported a Q3 loss of $0.10 per share, beating EPS estimates but missing revenue expectations with $1.29 million in quarterly revenue. The company has underperformed the market by 41.6% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' September 10, 2026 earnings report that disappointed Wall Street with weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.
Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' September 10, 2026 earnings report that disappointed Wall Street with weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.
Lifevantage reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.03 by 66.67%, but revenues of $37.12 million missed expectations by 3.84%. The company's year-over-year performance declined significantly with EPS down from $0.18 and revenues down from $47.56 million. The stock has underperformed the S&P 500 by 23.1% year-to-date and carries a Zacks Rank #3 (Hold) rating.
Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' September 10, 2026 earnings report that disappointed Wall Street with weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jul 26, 2023
$0.0075
Aug 11, 2023
recurring
Jan 20, 2023
$0.0075
Feb 10, 2023
recurring
Jul 26, 2022
$0.0075
Aug 11, 2022
recurring
Jan 20, 2022
$0.0075
Feb 9, 2022
recurring
Jul 26, 2021
$0.0075
Aug 11, 2021
recurring
Stock splits
Historical share-structure events and their execution dates.